Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Study ID: NCT05797831
Start Date: 2023-07-17
End Date: 2027-07
Study Type

Interventional

Study Phase

Phase3

No. of Participants

268

Intervention / Treatment

Navtemadlin

Navtemadlin Placebo

Sponsor

Kartos Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Ultrahypofractionation and Normal Tissue Toxicity

Study ID: NCT05912231
Start Date: 2023-08-15
End Date: 2025-09-17
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Accelerated Proton Beam Radiation Therapy (PBT)

Accelerated Photon Radiation Therapy (XRT)

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

Study ID: NCT05103631
Start Date: 2021-06-17
End Date: 2039-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

27

Intervention / Treatment

CATCH T cells

Sponsor

Baylor College of Medicine

Source: clinicaltrials.gov

Share:
Add to list

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

Study ID: NCT03909282
Start Date: 2019-03-22
End Date: 2025-09
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Lumpectomy

Partial breast irradiation prior to surgery

Sponsor

Stanford University

Source: clinicaltrials.gov

Share:
Add to list

A Pilot and Feasibility Study of a Dietary Intervention with Low-protein Meals in Cancer Patients Receiving Immunotherapies

Study ID: NCT05356182
Start Date: 2022-05-04
End Date: 2025-04
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Diet

Sponsor

State University of New York at Buffalo

Source: clinicaltrials.gov

Share:
Add to list

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Study ID: NCT05611931
Start Date: 2023-04-18
End Date: 2028-01-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

220

Intervention / Treatment

Selinexor

Matching Placebo for selinexor

Sponsor

Karyopharm Therapeutics Inc

Source: clinicaltrials.gov

Share:
Add to list

Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

Study ID: NCT06329531
Start Date: 2024-07-12
End Date: 2027-12-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

80

Intervention / Treatment

Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Study ID: NCT04886531
Start Date: 2022-07-21
End Date: 2025-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Neratinib

(L) or Anastrozole (A)

Trastuzumab

Sponsor

Ruth O'Regan

Source: clinicaltrials.gov

Share:
Add to list

A Study on Pain After Breast Reconstruction

Study ID: NCT06627582
Start Date: 2024-10-01
End Date: 2027-10-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment

PROMIS Scale v2.0 - Pain Intensity 3a

PROMIS 29+2

PROMIS Scale v2.0 - Nociceptive Pain Quality 5a

PROMIS Scale v2.0 - Neuropathic Pain Quality 5a

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Study ID: NCT06745882
Start Date: 2025-01-21
End Date: 2030-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

318

Intervention / Treatment

Cisplatin

Carboplatin

Pemetrexed

Pembrolizumab

Abraxane

Paclitaxel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Source: clinicaltrials.gov

Share:
Add to list